JP7778148B2 - 四価ＦＺＤ及びＷＮＴコレセプター（ｃｏ－ｒｅｃｅｐｔｏｒ）結合抗体分子並びにその使用 - Google Patents

四価ＦＺＤ及びＷＮＴコレセプター（ｃｏ－ｒｅｃｅｐｔｏｒ）結合抗体分子並びにその使用

Info

Publication number
JP7778148B2
JP7778148B2 JP2023537572A JP2023537572A JP7778148B2 JP 7778148 B2 JP7778148 B2 JP 7778148B2 JP 2023537572 A JP2023537572 A JP 2023537572A JP 2023537572 A JP2023537572 A JP 2023537572A JP 7778148 B2 JP7778148 B2 JP 7778148B2
Authority
JP
Japan
Prior art keywords
seq
heavy chain
chain monomer
cdr
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023537572A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554500A (ja
JP2023554500A5 (https=
JPWO2022130342A5 (https=
Inventor
アンガース、ステファヌ
シドゥ、サチデブ
ブレイザー、レヴィ
アダムス、ジャレット
セシャギリ、ソマセカール
Original Assignee
アントラーエイ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アントラーエイ セラピューティクス インコーポレイテッド filed Critical アントラーエイ セラピューティクス インコーポレイテッド
Publication of JP2023554500A publication Critical patent/JP2023554500A/ja
Publication of JP2023554500A5 publication Critical patent/JP2023554500A5/ja
Publication of JPWO2022130342A5 publication Critical patent/JPWO2022130342A5/ja
Priority to JP2025197132A priority Critical patent/JP2026041774A/ja
Application granted granted Critical
Publication of JP7778148B2 publication Critical patent/JP7778148B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023537572A 2020-12-18 2021-12-17 四価ＦＺＤ及びＷＮＴコレセプター（ｃｏ－ｒｅｃｅｐｔｏｒ）結合抗体分子並びにその使用 Active JP7778148B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025197132A JP2026041774A (ja) 2020-12-18 2025-11-18 四価ＦＺＤ及びＷＮＴコレセプター（ｃｏ－ｒｅｃｅｐｔｏｒ）結合抗体分子並びにその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063127408P 2020-12-18 2020-12-18
US63/127,408 2020-12-18
PCT/IB2021/061972 WO2022130342A1 (en) 2020-12-18 2021-12-17 Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025197132A Division JP2026041774A (ja) 2020-12-18 2025-11-18 四価ＦＺＤ及びＷＮＴコレセプター（ｃｏ－ｒｅｃｅｐｔｏｒ）結合抗体分子並びにその使用

Publications (4)

Publication Number Publication Date
JP2023554500A JP2023554500A (ja) 2023-12-27
JP2023554500A5 JP2023554500A5 (https=) 2025-05-20
JPWO2022130342A5 JPWO2022130342A5 (https=) 2025-05-20
JP7778148B2 true JP7778148B2 (ja) 2025-12-01

Family

ID=82058983

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023537572A Active JP7778148B2 (ja) 2020-12-18 2021-12-17 四価ＦＺＤ及びＷＮＴコレセプター（ｃｏ－ｒｅｃｅｐｔｏｒ）結合抗体分子並びにその使用
JP2023537540A Pending JP2024500839A (ja) 2020-12-18 2021-12-17 四価ＦＺＤ及びＷＮＴコレセプター（ｃｏ－ｒｅｃｅｐｔｏｒ）結合抗体分子並びにその使用
JP2025197132A Pending JP2026041774A (ja) 2020-12-18 2025-11-18 四価ＦＺＤ及びＷＮＴコレセプター（ｃｏ－ｒｅｃｅｐｔｏｒ）結合抗体分子並びにその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023537540A Pending JP2024500839A (ja) 2020-12-18 2021-12-17 四価ＦＺＤ及びＷＮＴコレセプター（ｃｏ－ｒｅｃｅｐｔｏｒ）結合抗体分子並びにその使用
JP2025197132A Pending JP2026041774A (ja) 2020-12-18 2025-11-18 四価ＦＺＤ及びＷＮＴコレセプター（ｃｏ－ｒｅｃｅｐｔｏｒ）結合抗体分子並びにその使用

Country Status (11)

Country Link
US (3) US20250270332A1 (https=)
EP (3) EP4263617A4 (https=)
JP (3) JP7778148B2 (https=)
KR (1) KR20230122077A (https=)
CN (2) CN116917332A (https=)
AU (2) AU2021399278A1 (https=)
CA (2) CA3204321A1 (https=)
CL (2) CL2023001768A1 (https=)
IL (2) IL303344A (https=)
MX (1) MX2023007103A (https=)
WO (2) WO2022130342A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3732201A4 (en) 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SURROGATES AND THEIR USES
CN120025448A (zh) * 2019-06-11 2025-05-23 安托拉诊疗公司 多价fzd和wnt结合分子及其用途
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2023130055A2 (en) * 2021-12-31 2023-07-06 Surrozen Operating, Inc. Wnt receptor-specific compound and method relating thereto
WO2024007008A2 (en) * 2022-06-30 2024-01-04 The University Of Chicago Cd73 (nt5e) targeting polypeptides
WO2024227103A1 (en) * 2023-04-27 2024-10-31 Surrozen Operating, Inc. Molecules modulating wnt signaling pathways and uses thereof
WO2025019458A2 (en) * 2023-07-14 2025-01-23 The Trustees Of Columbia University In The City Of New York Specific blood retinal barrier defect in glaucoma directs new treatments and clinical tests
WO2025168716A1 (en) 2024-02-07 2025-08-14 Eyebiotech Limited Compositions, doses, and methods for treatment of ocular diseases
WO2025176847A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Ocular delivery of active agents via microalgae extracellular vesicles
US20260092125A1 (en) * 2024-09-06 2026-04-02 Eyebiotech Limited Multivalent fzd4, wnt co-receptor, and vegf binding molecules and uses thereof
WO2026055312A1 (en) * 2024-09-06 2026-03-12 Merck Sharp & Dohme Llc Multivalent fzd4, wnt co-receptor, and vegf receptor molecules and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019159084A1 (en) 2018-02-14 2019-08-22 Angers Stephane Multivalent binding molecules activating wnt signaling and uses thereof
WO2020010308A1 (en) 2018-07-05 2020-01-09 Surrozen, Inc. Multi-specific wnt surrogate molecules and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
CN103002911B (zh) 2008-09-26 2015-08-26 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
EP2804629A1 (en) 2012-01-18 2014-11-26 Genentech, Inc. Anti-lrp5 antibodies and methods of use
DE102012202081A1 (de) 2012-02-13 2013-08-14 Osram Gmbh Glühfaden für elektrische lampen und elektrische lampe sowie herstellungsverfahren für einen glühfaden
AU2014246658B2 (en) 2013-04-03 2018-10-04 Peter Maccallum Cancer Institute Antibodies against human RYK and uses therefor
US9237411B2 (en) 2013-07-25 2016-01-12 Elwha Llc Systems and methods for providing one or more functionalities to a wearable computing device with directional antenna
EP3033356B1 (en) 2013-08-14 2020-01-15 Sachdev Sidhu Antibodies against frizzled proteins and methods of use thereof
JP6865688B2 (ja) 2015-01-16 2021-04-28 ジュノー セラピューティクス インコーポレイテッド Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体
US10919968B2 (en) 2016-01-29 2021-02-16 Modmab Therapeutics Corporation Frizzled5 protein-binding agents
WO2018026942A1 (en) 2016-08-02 2018-02-08 Merrimack Pharmaceuticals, Inc. Heteromeric polypeptides
US11039659B2 (en) 2017-09-07 2021-06-22 Nike, Inc. Sole structure for article of footwear
US10671121B2 (en) 2018-09-14 2020-06-02 Apple Inc. Magnetic layout in electronic devices and accessory devices for electronic devices
CN120025448A (zh) * 2019-06-11 2025-05-23 安托拉诊疗公司 多价fzd和wnt结合分子及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019159084A1 (en) 2018-02-14 2019-08-22 Angers Stephane Multivalent binding molecules activating wnt signaling and uses thereof
WO2020010308A1 (en) 2018-07-05 2020-01-09 Surrozen, Inc. Multi-specific wnt surrogate molecules and uses thereof

Also Published As

Publication number Publication date
CA3204322A1 (en) 2022-06-23
JP2026041774A (ja) 2026-03-10
JP2023554500A (ja) 2023-12-27
US20240132600A1 (en) 2024-04-25
WO2022130341A1 (en) 2022-06-23
EP4543921A2 (en) 2025-04-30
MX2023007103A (es) 2023-06-27
WO2022130342A4 (en) 2022-08-11
US20240228631A9 (en) 2024-07-11
EP4263618A4 (en) 2024-11-20
US20230118983A1 (en) 2023-04-20
AU2021404080A1 (en) 2023-06-29
CA3204321A1 (en) 2022-06-23
EP4263617A4 (en) 2025-01-01
EP4263618A1 (en) 2023-10-25
EP4263617A1 (en) 2023-10-25
CL2025001491A1 (es) 2025-08-22
CL2023001768A1 (es) 2024-01-12
CN116917332A (zh) 2023-10-20
IL303344A (en) 2023-08-01
CN116964102A (zh) 2023-10-27
WO2022130342A1 (en) 2022-06-23
IL303342A (en) 2023-08-01
AU2021399278A1 (en) 2023-06-29
KR20230122077A (ko) 2023-08-22
JP2024500839A (ja) 2024-01-10
US20250270332A1 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
JP7778148B2 (ja) 四価ＦＺＤ及びＷＮＴコレセプター（ｃｏ－ｒｅｃｅｐｔｏｒ）結合抗体分子並びにその使用
JP7550647B2 (ja) Ｗｎｔシグナル伝達を活性化する多価結合分子およびその使用
JP7377288B2 (ja) 多価ｆｚｄおよびｗｎｔ結合分子とその使用
KR102444797B1 (ko) α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도
WO2023250402A2 (en) Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
US20260092109A1 (en) Multivalent fzd4, wnt co-receptor, and vegf receptor molecules and uses thereof
US20260092125A1 (en) Multivalent fzd4, wnt co-receptor, and vegf binding molecules and uses thereof
BR122025000610A2 (pt) Molécula de anticorpo de ligação tetravalente, composição farmacêutica, uso, molécula de ácido nucleico, vetor e célula hospedeira
WO2022127066A9 (zh) 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
EA052880B1 (ru) Связывающие fzd и корецептор wnt молекулы четырехвалентного антитела и их применение

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A525

Effective date: 20230807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251022

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251118

R150 Certificate of patent or registration of utility model

Ref document number: 7778148

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150